Acadia's Nuplazid May Need Difficult Post-Market Trial, Panel Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Psychopharmacologic Drugs Advisory Committee votes that efficacy and safety were shown, but wants a post-marketing trial, although FDA is unsure how to design it.